Stockreport

CTI BioPharma Announces Completion of Enrollment in the Phase 2 PAC203 Study of Pacritinib

CTI BioPharma Corp.  (CTIC) 
Last cti biopharma corp. earnings: 11/1 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: ctibiopharma.com
PDF SEATTLE, Dec. 28, 2018 /PRNewswire/ -- CTI BioPharma Corp. (NASDAQ:CTIC) announced today the completion of full enrollment of 150 patients in the PAC203 Phase 2 study of [Read more]